Galway, Ireland, September 24, 2025 – Medtronic Neurovascular, a pioneer and global leader in stroke care, is proud to announce the appointment of Dr. Adam S. Arthur as Chief Medical Officer, effective September 30, 2025. Dr. Arthur brings more than 20 years of experience as a practicing neurosurgeon, having previously served as Chair of Neurosurgery at the University of Tennessee Health Science Center. His leadership in clinical trials and commitment to innovation have driven improved outcomes for stroke patients and advanced the field of neurovascular care.

Dr. Arthur’s addition to Medtronic Neurovascular exemplifies the company’s founding principle: bringing clinical expertise to industry. For more than 75 years, Medtronic’s success has been built on the partnership between physicians and engineers—a collaboration that continues to accelerate advancements in patient care and shape the future of Neurosciences.

“It’s an exciting time to be a part of the Neurovascular team as we focus on creating future breakthroughs in stroke care,” said Linnea Burman, President, Medtronic Neurovascular. “I’m confident Dr. Arthur will play an important role in advancing our goal of helping more stroke patients access world-class neurovascular care.”

“I’m excited and honored to join the team at Medtronic Neurovascular as Chief Medical Officer,” said Dr. Adam Arthur, Chief Medical Officer, Medtronic Neurovascular. “My top priority is improving care for patients, and this role allows me to be closer to the innovations that will deliver better patient outcomes.”

In his new role, Dr. Arthur will guide clinical development strategy, strengthen relationships within the physician community, and further Medtronic’s commitment to continually improving patient outcomes. Dr. Arthur will continue to devote a portion of his time to patient care through his practice at Semmes Murphey and remain on the faculty at University of Tennessee’s Health Science Center’s College of Medicine.

About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit www.Medtronic.com and follow Medtronic on LinkedIn.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

Contacts:
Kelli Lynch
Public Relations
+1-203-500-3328

Ryan Weispfenning
Investor Relations
+1-763-505-4626